Cannabis use is linked to a higher chance of psychotic symptoms and psychotic disorders. The research points to heavier and more frequent use, and to starting at a younger age, as the patterns that carry the most risk. The CDC and several published reviews describe an association rather than a settled cause, and the reviewers do not state their conclusions with the same strength. If psychotic symptoms have followed cannabis use, the next step is an assessment by a qualified mental health or medical professional.
What associations are reported?
The CDC’s cannabis and mental health page says that people who use cannabis are more likely to develop psychosis, which it describes as not knowing what is real, hallucinations, and paranoia. It adds that the link with schizophrenia is stronger in people who start using cannabis at an earlier age and use it more often.
The strongest figures come from a 2016 meta-analysis in Schizophrenia Bulletin. Ten studies entered the analysis, enrolling 66,816 people in total. The heaviest cannabis users had an odds ratio of 3.90 (95% CI 2.84 to 5.34) for schizophrenia and other psychosis-related outcomes compared with non-users. Higher levels of use were linked to higher risk in every included study, and the authors say the findings confirm a dose-response relationship (2016 meta-analysis on level of use and psychosis risk).
A 2020 review of reviews in the European Archives of Psychiatry and Clinical Neuroscience (review of reviews on cannabis use and psychosis) pulled together 26 systematic reviews and meta-analyses. Its authors report that psychotic illness arises more often in cannabis users than in non-users, that the risk is dose-dependent, and that users have an earlier onset of psychotic illness. In people who already have psychosis, the same review links cannabis use with higher relapse rates, more hospitalizations and more pronounced positive symptoms.
A 2023 review in Child and Adolescent Psychiatric Clinics of North America (2023 review on cannabis and psychosis) reports that cannabis use increases the risk of both attenuated (subthreshold) and acute psychotic symptoms. It also says use may worsen symptoms in young people who have underlying psychosis risk or a psychotic disorder.
Which factors complicate causal interpretation?
The main problem is study design. A 2016 review in Biological Psychiatry (2016 review of epidemiologic findings on cannabis and psychosis) says that establishing causality from observational designs can be problematic. The same review says further studies are needed to determine the size of the effect, the effect of different strains of cannabis, and which high-risk groups are most susceptible. For a plain explanation of why early findings are hard to read as cause, see Understanding Emerging Research: Preliminary Findings and What They Mean.
- Size of the effect. The 2016 review says the magnitude of the effect still needs to be determined.
- Strain. The same review says the effect of different strains on risk is not yet determined.
- Who is most at risk. High-risk groups are not yet fully identified, according to the same review.
- Study quality. The 2020 review of reviews rates the included reviews as ranging from high to poor quality.
- Shared vulnerability. The 2023 review says cannabis use may exacerbate psychosis symptoms among young people with underlying psychosis risk and psychotic disorders.
- Trial gaps. The 2023 review says there are many gaps in clinical trial research on treating co-occurring psychosis and cannabis use.
How firm are the conclusions?
The reviewers do not state their conclusions with the same strength, so read them side by side. The 2016 Biological Psychiatry authors say the findings are strong enough to warrant a public health message that cannabis use can increase the risk of psychotic disorders. The 2016 Schizophrenia Bulletin authors write that a causal link cannot be unequivocally established, but that there is sufficient evidence to justify harm reduction prevention programs. The 2023 review is the most cautious about treatment, pointing to gaps in trial research. These are the reviewers’ own conclusions, not formal clinical practice guidelines.
How common is cannabis-induced psychosis?
None of the studies above gives a rate for cannabis-induced psychosis on its own. What they report is group-level association. In the 2016 meta-analysis, the heaviest users had an odds ratio of 3.90 for schizophrenia and other psychosis-related outcomes compared with non-users. That is a figure for groups, not a personal risk estimate.
What is cannabis-induced psychosis?
Midwest Recovery Center, a treatment provider, describes cannabis-induced psychosis as a condition in which marijuana use triggers temporary psychotic symptoms that affect perception, thinking and emotional regulation. Its page says this can follow a single high dose or repeated heavy use, especially with high-THC products such as concentrates, vapes and potent edibles.
What are the symptoms and first signs?
The treatment provider lists hallucinations, delusions, intense paranoia or fear, disorganized or racing thoughts, confusion or trouble speaking clearly, and agitation or unpredictable behavior. Its warning signs that need immediate evaluation include hearing voices or seeing things others cannot, severe paranoia or irrational fears, confused or disorganized speech, loss of touch with reality, and aggressive, erratic or unsafe behavior. The CDC’s page adds disorientation and sometimes unpleasant thoughts or feelings of anxiety and paranoia among the effects of cannabis use.
Are there physical symptoms?
The symptoms above are mental and perceptual. If a physical change appears alongside them, tell a clinician, or call 911 if it is an emergency.
Can you tell when psychosis is coming?
The 2023 review reports that cannabis use increases the risk of attenuated, or subthreshold, psychotic symptoms. Its abstract does not describe a way to predict an episode in an individual. A clinician who assesses early symptoms is the right person to ask.
How long does it last, and can someone recover?
The treatment provider says some people recover within days, while others need weeks or months for symptoms to fully resolve. It also says most people recover within days to weeks after stopping cannabis and getting appropriate care, and that a smaller share may have ongoing symptoms that need long-term treatment. These are the provider’s statements. The studies above do not give a typical episode length.
The 2020 review adds a caution for people who already have psychosis: cannabis use was linked with higher relapse rates. None of the studies above addresses whether the brain returns to its earlier state after an episode, so ask a clinician about recovery in your situation.
What causes cannabis-induced psychosis?
The treatment provider says THC can disrupt normal brain signaling, particularly in people who are biologically or psychologically vulnerable. For background on how cannabinoids act on the body’s signaling system, see The Endocannabinoid System: How Hemp Compounds Work. The provider lists frequent or high-potency use, high stress or sleep deprivation, personal or family history of mental illness, younger age and prior episodes as risk factors. The CDC’s pattern of stronger association with earlier starting age and frequent use overlaps with that list. The causal question remains open: the 2016 meta-analysis says a causal link cannot be unequivocally established, and the 2016 Biological Psychiatry review says causality is hard to establish from observational designs.
Why does starting cannabis young matter?
Several sources point to younger people. The 2020 review of reviews reports earlier onset of psychotic illness among cannabis users. The CDC says the association with schizophrenia is stronger for people who start young. The 2023 review says use may worsen symptoms among young people who have underlying psychosis risk. None of these sources explains the biological reason for the age pattern, so that question belongs to a clinician or the primary studies.
What treatment is available?
The treatment provider lists stopping cannabis use, medical and psychiatric evaluation, antipsychotic medication when clinically appropriate, individual therapy, support groups, and ongoing monitoring. It says short-term inpatient care is sometimes recommended. The 2023 review suggests building cannabis use assessment and treatment into specialized early psychosis care, while noting many gaps in trial research. No specific antipsychotic is named in the studies above, and which medicine, if any, fits your situation is a decision for a clinician.
What should I do next?
Your next step is a qualified mental health assessment and a treatment plan. Bring a clear account of when symptoms started, how often cannabis was used and in what forms, and any family history of mental illness. For an emergency, call 911. If you are wondering how long cannabinoids remain in your system, see THC Detox Science: How Cannabinoids Leave the Body.
If cannabis use has become hard to control, a clinician can assess your cannabis use patterns. Tell your clinician about any other medicines you take, since the studies cited here do not address interactions.
Questions this page does not settle
Stage terms, diagnostic criteria in the DSM-5 manual, and individual stories are outside what the studies cited here cover. A clinician can walk you through each of them.
By TakeHempGummies.com Consumer Research Desk
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.